AEON · AEON Biopharma, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As a result of these conditions, management has concluded that substantial doubt about our ability to continue as a going concern exists as conditions and events, considered in the aggregate, indicate that it is probable that we will be unable to meet our obligations as they become due within one year after the date that the financial statements included in this Report are issued.”View the 10-Q filed Aug 12, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Feb 26, 2025; bars on opposite sides are not compared.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Expense related to increase in fair value of New Convertible Note | $0.2M | the three months ended June 30, 2026 filing | — |
| Gain related to decrease in fair value of Daewoong Warrants | $2.2M | the three months ended June 30, 2026 filing | — |
| net upfront proceeds | $13.6M | July 2026 | — |
| potential gross proceeds | $34M | July 2026 | — |
| U.S. therapeutic neurotoxin market | $3B | annually | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AEON
this stock
AEON Biopharma, Inc.
|
$12.55M | -73.3% | — | — | 2.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.8% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.27B | +4.6% | +20.8% | 19.6 | 2.3% |
|
ARGX
Argenx SE
|
$65.12B | +25.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Feb 26, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AEON | +52.3% | +15.3% | -72.3% | +0.3% | -73.3% |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | +51.2% | +11.3% | -87.0% | -2.9% | -86.4% |